AAAAAA

   
Results: 1-25 | 26-50 | 51-53
Results: 26-50/53
Docetaxel (Taxotere (R))-cisplatin (TC): An effective drug combination in gastric carcinoma
Authors: Roth, AD Maibach, R Martinelli, G Fazio, N Aapro, MS Pagani, O Morant, R Borner, MM Herrmann, R Honegger, H Cavalli, F Alberto, P Castiglione, M Goldhirsch, A
Citation: Ad. Roth et al., Docetaxel (Taxotere (R))-cisplatin (TC): An effective drug combination in gastric carcinoma, ANN ONCOL, 11(3), 2000, pp. 301-306
Parathyroid hormone-related protein in metastatic breast cancer induced hypercalcemia: A case report
Authors: Graffeo, R Pagani, O Crivelli, M Zappa, F Borella, P Reiner, M Goldhirsch, A
Citation: R. Graffeo et al., Parathyroid hormone-related protein in metastatic breast cancer induced hypercalcemia: A case report, ANN ONCOL, 11(1), 2000, pp. 97-100
Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required?
Authors: Orlando, L Colleoni, M Nole, F Biffi, R Rocca, A Curigliano, G Ferretti, G Peruzzotti, G de Braud, F Masci, G Goldhirsch, A
Citation: L. Orlando et al., Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required?, ANN ONCOL, 11(1), 2000, pp. 117-118
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII
Authors: Crivellari, D Bonetti, M Castiglione-Gertsch, M Gelber, RD Rudenstam, CM Thurlimann, B Price, KN Coates, AS Hurny, C Bernhard, J Lindtner, J Collins, J Senn, HJ Cavalli, F Forbes, J Gudgeon, A Simoncini, E Cortes-Funes, H Veronesi, A Fey, M Goldhirsch, A
Citation: D. Crivellari et al., Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII, J CL ONCOL, 18(7), 2000, pp. 1412-1422
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors
Authors: Colleoni, M Bonetti, M Coates, AS Castiglione-Gertsch, M Gelber, RD Price, K Rudenstam, CM Lindtner, J Collins, J Thurlimann, B Holmberg, S Veronesi, A Marini, G Goldhirsch, A
Citation: M. Colleoni et al., Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors, J CL ONCOL, 18(3), 2000, pp. 584-590
Identifying breast cancer patients at high risk for bone metastases
Authors: Colleoni, M O'Neill, A Goldhirsch, A Gelber, RD Bonetti, M Thurlimann, B Price, KN Castiglione-Gertsch, M Coates, AS Lindtner, J Collins, J Senn, HJ Cavalli, F Forbes, J Gudgeon, A Simoncini, E Cortes-Funes, H Veronesi, A Fey, M Rudenstam, CM
Citation: M. Colleoni et al., Identifying breast cancer patients at high risk for bone metastases, J CL ONCOL, 18(23), 2000, pp. 3925-3935
Quality-of-life scores predict outcome in metastatic but not early breast cancer
Authors: Coates, AS Hurny, C Peterson, HF Bernhard, J Castiglione-Gertsch, M Gelber, RD Goldhirsch, A
Citation: As. Coates et al., Quality-of-life scores predict outcome in metastatic but not early breast cancer, J CL ONCOL, 18(22), 2000, pp. 3768-3774
Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment
Authors: Sabbioni, MEE Siegrist, HP Bacchi, M Bernhard, J Castiglione, M Thurlimann, B Bonnefoi, H Perey, L Herrmann, R Goldhirsch, A Hurny, C
Citation: Mee. Sabbioni et al., Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment, BREAST CANC, 59(3), 2000, pp. 279-287
Depression and degree of acceptance of adjuvant cytotoxic drugs
Authors: Colleoni, M Mandala, M Peruzzotti, G Robertson, C Bredart, A Goldhirsch, A
Citation: M. Colleoni et al., Depression and degree of acceptance of adjuvant cytotoxic drugs, LANCET, 356(9238), 2000, pp. 1326-1327
False negatives in oestrogen-receptor assay - Reply
Authors: Aebi, S Gelber, S Castiglione-Gertsch, M Coates, AS Goldhirsch, A
Citation: S. Aebi et al., False negatives in oestrogen-receptor assay - Reply, LANCET, 356(9233), 2000, pp. 944-945
Taxanes as adjuvant for breast cancer
Authors: Goldhirsch, A Francis, P Castiglione-Gertsch, M Gelber, RD Coates, AS
Citation: A. Goldhirsch et al., Taxanes as adjuvant for breast cancer, LANCET, 356(9228), 2000, pp. 507-508
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Authors: Aebi, S Gelber, S Castiglione-Gertsch, M Gelber, RD Collins, J Thurlimann, B Rudenstam, CM Lindtner, J Crivellari, D Cortes-Funes, H Simoncini, E Werner, ID Coates, AS Goldhirsch, A
Citation: S. Aebi et al., Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?, LANCET, 355(9218), 2000, pp. 1869-1874
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma - Reply
Authors: Bertolini, F Paolucci, M Peccatori, F Cinieri, S Agazzi, A Ferrucci, PF Cocorocchio, E Goldhirsch, A Martinelli, G
Citation: F. Bertolini et al., Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma - Reply, BR J HAEM, 108(3), 2000, pp. 662-663
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: Formestane versus megestrol acetate as second-line hormonaltreatment
Authors: Bernhard, J Castiglione-Gertsch, M Schmitz, SFH Thurlimann, B Cavalli, F Morant, R Fey, MF Bonnefoi, H Goldhirsch, A Hurny, C
Citation: J. Bernhard et al., Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: Formestane versus megestrol acetate as second-line hormonaltreatment, EUR J CANC, 35(6), 1999, pp. 913-920
Prediction of response to primary chemotherapy for operable breast cancer
Authors: Colleoni, M Orvieto, E Nole, F Orlando, L Minchella, I Viale, G Peruzzotti, G Robertson, C Noberasco, C Galimberti, V Sacchini, V Veronesi, P Zurrida, S Orecchia, R Goldhirsch, A
Citation: M. Colleoni et al., Prediction of response to primary chemotherapy for operable breast cancer, EUR J CANC, 35(4), 1999, pp. 574-579
Postoperative radiotherapy 'improves survival' in postmenopausal breast cancer - Comment
Authors: Goldhirsch, A
Citation: A. Goldhirsch, Postoperative radiotherapy 'improves survival' in postmenopausal breast cancer - Comment, EUR J CANC, 35(10), 1999, pp. 1413-1414
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients
Authors: Sabbioni, MEE Castiglione, M Hurny, C Siegrist, HP Bacchi, M Bernhard, J Thurlimann, B Bonnefoi, H Perey, L Goldhirsch, A Senn, HJ
Citation: Mee. Sabbioni et al., Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients, SUPP CARE C, 7(3), 1999, pp. 149-153
Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN)
Authors: Nole, F Minchella, I Colleoni, M Orvieto, E Munzone, E de Braud, F Peruzzotti, G Martinelli, G Zampino, MG Catania, C Pizzamiglio, M Veronesi, P Zurrida, S Galimberti, V Goldhirsch, A Veronesi, U
Citation: F. Nole et al., Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN), ANN ONCOL, 10(8), 1999, pp. 993-996
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
Authors: Pagani, O Sessa, C Martinelli, G Crivellari, D Buonadonna, A Thurlimann, B Hess, D Borner, M Bauer, J Zampino, G Zimatore, M Graffeo, R Riva, A Goldhirsch, A
Citation: O. Pagani et al., Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer, ANN ONCOL, 10(5), 1999, pp. 539-545
Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin
Authors: Colombo, T Parisi, I Zucchetti, M Sessa, C Goldhirsch, A D'Incalci, M
Citation: T. Colombo et al., Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin, ANN ONCOL, 10(4), 1999, pp. 391-395
Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphoma
Authors: De Pas, T Martinelli, G De Braud, F Peccatori, F Catania, C Aapro, MS Goldhirsch, A
Citation: T. De Pas et al., Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphoma, ANN ONCOL, 10(11), 1999, pp. 1393-1393
Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (cmf regimen)
Authors: Locatelli, M Colleoni, M Noberasco, C Nole, F Orlando, L Munzone, E Peruzzotti, G Goldhirsch, A
Citation: M. Locatelli et al., Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (cmf regimen), ANN ONCOL, 10(11), 1999, pp. 1394-1395
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: Does quality of life matter?
Authors: Bernhard, J Thurlimann, B Schmitz, SFH Castiglione-Gertsch, M Cavalli, F Morant, R Fey, MF Bonnefoi, H Goldhirsch, A Hurny, C
Citation: J. Bernhard et al., Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: Does quality of life matter?, J CL ONCOL, 17(6), 1999, pp. 1672-1679
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
Authors: Cote, RJ Peterson, HF Chaiwun, B Gelber, RD Goldhirsch, A Castiglione-Gertsch, M Gusterson, B Neville, AM
Citation: Rj. Cote et al., Role of immunohistochemical detection of lymph-node metastases in management of breast cancer, LANCET, 354(9182), 1999, pp. 896-900
Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil
Authors: Colleoni, M Price, KN Castiglione-Gertsch, M Gelber, RD Coates, AS Goldhirsch, A
Citation: M. Colleoni et al., Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil, LANCET, 354(9173), 1999, pp. 130-131
Risultati: 1-25 | 26-50 | 51-53